MI HB4350

Modifies definitions in the Health Care False Claim Act to replace outdated references with current Michigan Compiled Law citations for health care corporations and HMOs.

Changes language throughout from "which" to "that" for grammatical consistency in defining terms like "deceptive," "health care insurer," and "knowing."

Creates a two-tiered exemption for drug manufacturer rebates and discounts: through December 31, 2022, all rebates qualify for exemption; beginning January 1, 2023, rebates are only exempt if the drug lacks a generically equivalent alternative or if specific conditions apply (prior authorization, step-therapy, prescriber directive, or FDA Risk Evaluation and Mitigation Strategy requirements).

Defines "generically equivalent drug product" as a drug with FDA therapeutic equivalence designation that is nationally available, establishing the threshold for when post-2022 rebate restrictions apply.

Adds "Administration" definition (injection, infusion, or similar application) and clarifies that the exemption does not alter copayment, deductible, or other cost-sharing requirements under health insurance contracts.